Functional selectivity describes the ability of ligands to differentially regulate multiple signalling pathways when coupled to a single receptor, and the operational model is commonly used to analyse these data. Here, we assess the mathematical properties of the operational model and evaluate the outcomes of fixing parameters on model performance.
Introduction
Ever since the earliest description of receptor-ligand interactions (Clark, 1926) , attempts to develop a reliable method for their quantification have been made. The E max model provides an empirical justification for the concentration-response relationship. It makes the assumption that the effect of the ligand is directly proportional to receptor occupancy; that is to say, maximal response can only be achieved with maximal receptor occupancy (Clarke and Bond, 1998 ). The operational model relaxes this assumption by incorporating an (unobserved) empirical transducer function to convert occupancy into effect (Black and Leff, 1983) , which allows the effect to represent a potential cascade of cellular or tissue signalling. This can explain the 'receptor reserve' phenomenon, that is, stimulation of only a fraction of the whole receptor population elicits an apparent maximal response. Furthermore, incorporation of the transducer function also allows the investigator to create a link directly from ligand concentration to response without the need to formally incorporate ligand binding as a necessary intermediary step. In this sense, the operational model is a 'middle-out' strategy in receptor theory which keeps the balance between model simplicity and mechanistic insight. Here, the equation for the operational model (Equation 1), in the same style as Equation 5 from the original paper (Black and Leff, 1983) , is given:
In the operational model described by Black and Leff, there are two key parameters: τ and K A . This is a reparameterization (of Equation 1 here) by Black and Leff which they present in their Equation 6 (shown in this paper in Equation 5). The transducer ratio parameter, τ ( R0 KE ), encompasses receptor density (R 0 ) and the stimulus coupling efficiency (K E ). K A is an implicit parameter in the model that accounts for ligand binding but is not specifically estimated in their work. In more recent developments, the operational model has been generalized into several variants, such as the conformation-based operational model (Roche et al., 2013 ) and the operational model with constitutive activity (Slack and Hall, 2012) . Among these variants, the general operational model (Equation 2 ) is the most widely used model that accounts for non-zero basal (Basal), non-unity Hill slope factor (n) and estimable maximal system response (E m ) (van der Westhuizen et al., 2014) . Furthermore, it is evident within the operational model framework that the classical concepts of 'full agonism' and 'partial agonism' need further examination, as such classifications are made on the combination of ligand attributes and how efficiently the system transduces the stimulus into effect (Kenakin, 2014) . It is possible that one single ligand may appear to be a full agonist in an efficient transduction system but a partial agonist in a less efficient transduction system.
Recently, interest has arisen in the ability of ligands to differentially regulate different signalling pathways when coupled to a single receptor; a concept termed functional selectivity (Urban et al., 2007) . The need to link ligand concentration to response at (now) multiple pathways has rejuvenated interest in the operational model. In such studies, it is common to consider a single composite parameter, R, in quantifying a ligand's effect on a pathway. This parameter is defined as the ratio τ KA and is termed the transduction coefficient. It is derived from an application of the operational model to simultaneously account for both affinity and efficacy of a ligand (Kenakin and Miller, 2010) . Because the system itself will complicate interpretation of this composite parameter (e.g. system bias and observation bias), it is necessary to normalize R to a reference ligand, yielding the normalized transduction coefficient Δ log (R) (Kenakin et al., 2012) . Finally, as the goal of the analysis is to consider how a ligand may bias the response to a particular pathway, it is convention to further normalize the transduction coefficient for one pathway to another, thereby providing a single metric to encapsulate the relative effect of a ligand on a pathway of interest compared to a reference pathway. The additional normalization leads to the now widely used metric ΔΔ log (R) (Kenakin et al., 2012) .
In this work, we explore the mathematical and statistical properties of the operational and the general operational model in relation to parameter estimation, which is termed identifiability analysis. A model that contains one or more parameters that are not able to be estimated (given perfect data) is termed not identifiable. In other words, identifiability analysis answers the question of whether there is a unique solution for the parameters of a mathematical model based on its structure and also the experimental design (Shivva et al., 2013; Lavielle and Aarons, 2016) . This concept is more commonly considered in pharmacokinetic studies where, for instance, it is known that if you only administer a drug orally to an individual, then the parameter absolute bioavailability (F) cannot be estimated (as it requires both intravenous and oral administration to provide the data for this parameter). As such, this parameter is said to be not identifiable. When model parameters are not identifiable, this means that there are an infinite number of solutions for the model parameters that can fit the data equally well. This causes the parameters of the model to be imprecisely estimated and potentially misrepresent the data. Identifiability issues are also present in pharmacological experiments, but these properties are less well explored. The concept of identifiability is divided into two types: (i) structural identifiability and (ii) deterministic identifiability (sometimes also termed pragmatic identifiability). Structural identifiability is a formal mathematical technique to determine whether a parameter can be uniquely estimated given perfect data (data that contain no error of any type -e.g. no assay error) (Bellman and Åström, 1970) . Deterministic identifiability addresses the degree of precision with which a parameter can be estimated based on typical experimental data (Guedj et al., 2007) . These concepts are naturally hierarchical, such that if a model is not structurally identifiable, then it cannot be applied to any data and one or more parameters will need to be either fixed or merged into a composite parameter (the latter is analogous to fixing one of the parameters to a null value; e.g. 0 or 1). Once a model is structurally identifiable, then the lower hierarchy, deterministic identifiability, yields knowledge about how well it can be estimated by a given experiment. These concepts are critical in understanding how a model can represent a given set of experimental data.
Application of the operational model to describe the responses elicited by a ligand in multiple pathways is known to result in issues with mathematical identifiability of the model (Kenakin et al., 2012; van der Westhuizen et al., 2014) . It should be noted that application of the operational model does not explicitly include ligand binding and considers a single pathway from a single ligand at a time (hence the need for normalization). It is, in theory, possible to apply a general equilibrium model that encompasses all pathways simultaneously that would obviate some of these mathematical issues, but this is beyond the scope of this work.
The overarching aim of this paper is to provide a readyto-use understanding of the application of the operational model for quantifying functional selectivity. This encompasses three specific objectives: (i) to systematically assess the identifiability (structural and deterministic) of both the operational model and the general operational model; (ii) to evaluate the effects of parameter mis-specification on the quantification of ligand bias; and (iii) to assess whether we can relax the need for the presence of a full agonist to quantify ligand bias.
Methods
The methods are described in two parts. In the first part, the technical details of the methodology are provided as they relate to both structural and deterministic identifiability as well as simulation estimation methods. In the second part, methods are provided for each of the three aims.
Part 1
Structural identifiability analysis. This type of identifiability determines whether a unique set of parameter values exist within the model, given perfect data. If this is not true, then the model is said to be not identifiable. This means that the model parameters cannot be estimated in its current form and a parameter (or parameters) will need to be fixed. The structural identifiability analysis followed the processes developed in previous work (Shivva et al., 2013) . The Population OPTimal design for Identifiability (POPT_I), a MATLAB-based software (available at http://www.otago.ac. nz/pharmacometrics/downloads/index.html), was used for the assessment of structural identifiability. Brief details of the application of this method are provided here for completeness. In this work, two necessary criteria for claiming a structurally identifiable, fixed-effect model were adopted: (i) there was a continuous linear log-log relationship between the log of the determinant of Fisher information matrix (M F ) and the log of the random noise; (ii) the determinant should approach infinity as residual variance approaches zero (Shivva et al., 2013) . The values for the random noise log(σ 2 ) were the same for all analyses, À7, À6, À5, À4, À3, À2, À1, 0, 1 and 2.
Deterministic identifiability analysis. Deterministic identifiability is concerned with the precision of parameter estimation. The relative magnitude of the SE is an indication of the precision of the parameter estimates and is amenable to the experimental design. The SE value can be obtained either theoretically, via the Fisher information matrix (M F ), or they can be obtained after a data set has been analysed using standard software (such as GraphPad Prism® Briefly, and for completeness, the SE values are calculated as the square root of the diagonal elements of the inverse of the M F . The M F can be calculated as the product of the sensitivity matrices weighted by the residual error. In this work, optimal design software PFIM (Bazzoli et al., 2010) , available at http://www.pfim.biostat.fr/, was used to calculate the M F and provide the expected SE values.
Stochastic simulation and estimation (SSE)
Outline of stochastic simulation estimation (SSE) unit. In practice, the slope factor n is commonly added to improve curve fitting. Hence, we intend to explore a range of values of n to assess their influence on the results of this analysis. We tried an exact numerical evaluation, but it became unfeasible (this failure is shown in the Supporting Information). A more general method involving simulating data and estimating the model parameters was therefore used. This is termed stochastic simulation and estimation (SSE). Practically, this method requires the data to be simulated with random error (aka 'experimental noise'), termed stochastic simulation, and then estimated using an appropriate software application. It is common to use SSE methods when the model is too complicated to perform exact mathematical analyses. Both the simulation (SSE) method and exact calculation (when possible) provide equivalent answers and interpretations.
The SSE methods in this work were used to assess the influence of mis-specification of parameter values (i.e. when the parameters were fixed to something other than their true value). Each SSE unit consists of three steps: dataset simulation, parameter estimation and analysis of the results. In the simulation step, based on the given parameter values and study design, pseudo-experimental data were generated from the general operational model (Equation 2) using R version 3.0.2 (http://www.r-project.org/) within Rstudio IDE Version 0.98.490 (http://www.rstudio.com/). In total, there were 1000 replicates. In each replicate, two concentration-response curves corresponding to a pair of reference and test ligands were generated with random error. Then, in the estimation step, each replicate was analysed in GraphPad Prism (v7.0; GraphPad Software, La Jolla, CA, USA) following usual estimation methods (van der Westhuizen et al., 2014) . R code for stochastic simulation and GraphPad Prism code for batch analysis are included in the Supporting Information. In the post-estimation analysis step, the normalized transduction coefficient (Δ log (R)) value was calculated for each replicate by taking the difference of log(R) between reference and test ligand. For the final outcome of each SSE unit, only the results from the replicates with successful estimation were included and contributed to calculation of the median and 95% confidence intervals (CI) for log(R) and Δ log (R).
Criteria for successful estimation. A successful estimation was defined as not ambiguous estimates of the parameter log (R) for the pair of ligands in a replicate. The term ambiguous is a term coined by Prism to describe the case that the parameters cannot be precisely estimated. This is akin to defining the parameters as not deterministically identifiable. Such parameters are marked in Prism with a '~' before the best fit values. Ambiguous values were omitted from further computation. The successful estimation rate was defined as the fraction of successful estimation runs within 1000 replicates. In general, the estimation method was considered to be robust if its successful estimation rate was higher than 90%.
Part 2 Systematic assessment of the identifiability of both the operational model and the general operational model
Structural identifiability analysis. The original form of the operational model (Equation 1) has been extended into the general operational model (Equation 2, the same as Equation 5 in van der Westhuizen et al., 2014) to account for non-zero basal (Basal), non-unity slope factor (n) and an estimable maximal system response (E m ) (van der Westhuizen et al., 2014) .
Here, E m is the system maximal response, Basal is the baseline response in the absence of ligand and n is the slope factor. These three parameters are system parameters. Note, in this expression, it is assumed that the basal activity of the system is constant over both time and applied ligand concentrations. Further generalization is possible but not considered here. Both K A and R are drug-specific parameters. Conventionally, the parameters K A and R are transformed into logarithms (i.e. 10 log KA ð Þ ; 10 log R ð Þ ). Note here that this re-parameterization does not affect the structural identifiability of the model.
The structural identifiability analysis (a formal assessment of the model to determine if the parameters could be uniquely estimated) was performed on both the Black and Leff operational model (Equation 1) and the general operational model (Equation 2) in POPT_I. A generic study design with sampling concentrations log(A) from À13 to À4, increment of 1, was assumed for both models. An arbitrary set of parameter values was used (Table 1) . [Since this work is dependent on the particular set of parameter values, then the structural identifiability analysis is said to be local -meaning the model is identifiable (or not) based on a specific set of parameter values. This does not affect interpretation of this work.] Structural identifiability was assessed for the Black and Leff operational model based on four scenarios: (i) all the model parameters (R 0 , K E , K A ) were considered to be unknown and estimable; (ii) R 0 was assumed to be known and fixed; (iii) K E was assumed to be known and fixed; and (iv) R 0 and K E were reduced into one single parameter τ, and both τ and K A were considered to be unknown and estimable. For the general operational model, four scenarios were evaluated for the identifiability analysis: (i) all the model parameters (E m , log(K A ), log(R)) were considered to be unknown and estimable; (ii) E m was assumed to be known and fixed; (iii) log(K A ) was assumed to be known and fixed; and (iv) log(R) was assumed to be known and fixed.
Deterministic identifiability analysis. A deterministic identifiability analysis (assessment of SEs of the parameter estimates) was performed on both the operational model and the general operational model. A similar parameter setup was used as in the structural identifiability analysis. Details are provided in Table 2 . A proportional measurement error with 10% coefficient of variation was assumed for data arising under both models. The deterministic identifiability was assessed for each value of τ. In terms of the general operational model, three arbitrary sets of the parameter values were used and each stood for one of the following circumstances: (i) a pair of highly efficacious ligands; (ii) one highly efficacious ligand and one less efficacious ligand; and (iii) a pair of low-efficacy ligands (Table 3) . Efficacy is defined based on τ values. Under each circumstance, two scenarios were evaluated for the deterministic identifiability: (i) E m was assumed to be known and fixed; and (ii) K A values of both ligands were assumed to be known and fixed.
Table 1
The parameter values for structural identifiability analysis of the operational model
Parameters

Operational model
General operational model À7, À6, À5, À4, À3, À2, À1, 0, 1, and 2
Evaluation of the effects of parameter mis-specification on the quantification of ligand bias
Current estimation methods for the quantification of ligand bias. In current practice, three methods have been adopted for the estimation of the general operational model. In method I, the value of system maximal response (E m ) is set to the empirically measured response of a known maximal stimulant (e.g., forskolin for cyclic AMP and phorbol 12-myristate 13-acetate for phosphorylated ERK) or the common maximal response among multiple ligands (Kenakin et al., 2012) . In method II, the equilibrium dissociation constant (K A ) is fixed to a previously estimated value from a separate binding assay (Rajagopal et al., 2011) . In method III, a slight modification is made into the operational model framework (van der Westhuizen et al., 2014) . In this method, ligands are subjectively classified into two categories: full and partial agonists, based on the value of observed maximal response of each ligand (E max, i ). For partial agonists, the concentration-response curve is directly fitted to the general operational model, whereas for full agonists, one more constraint is applied with K A arbitrarily assigned to 1 mol·L À1 (the identity for most mathematical operations), a value typically 6 to 8 orders of magnitude from expected.
SSE study I: evaluation of the effects of mis-specified E m . SSE study I was performed to evaluate the effects of mis-specified E m on the quantification of ligand bias. For the simulation step, a generic study design for the sampling concentrations (Table 4) was assumed for all the SSE units and three arbitrary sets of the parameter values (Table 4) were used with the only difference in slope factor (n=[0.7, 1, 1.5]). Then, in the estimation step, for these three simulated datasets, each was used to estimate the parameters using estimation method I with E m fixed to three different values 0.8, 1(true) or 1.2. Therefore, there were nine SSE units in this SSE study.
SSE study II: Evaluation of the effects of mis-specified K A . SSE study II was conducted to evaluate the effects of mis-specified K A on the quantification of ligand bias. In the simulation step, a generic study design for the sampling concentrations (Table 4) was assumed for all the SSE units and 10 arbitrary sets of the parameter values (Table 4) were used with the only difference in slope factor (n=[0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.25, 1.5, 1.75, 2]). The value of τ for the reference ligand was assigned to a large number (Table 4 ) to represent full agonist (i.e. highly efficacious ligand). In the following, each simulated data were estimated by two different estimation methods: method II with K A values fixed to true or method III with K A of full agonist arbitrarily assigned to 1 mol·L À1 . In the final step, the post-estimation analysis was applied to get summarized outcomes from these 20 SSE units.
Assessment of the relaxation of the need for a full agonist in quantifying functional selectivity
Method IV for the quantification of ligand bias. The current estimation method for the general operational model requires a full agonist to have been identified within the study. We propose a generalization to this estimation method (termed method IV here) to account for the situation when only lowefficacy ligands are present. The key steps were listed: Table 3 The parameter values for deterministic identifiability analysis of the general operational model 
Here, Basal and n are system parameters shared among different ligands. E max and logEC 50 are ligand-specific parameters 2) Select the ligand with maximal E max,i from the current study and set as if it were a full agonist (termed pseudo full agonist). Classify all the remaining ligands as partial agonists. 3) For partial agonists, the concentration-response curve is directly fitted with the general operational model, whereas for the pseudo full agonist, the value of K A is set to 1 mol·L À1 . For each pathway, the values of n, Basal and E m are shared for all the ligands and there is no constraint on the values of log(R) and log(K A ).
An illustrating example with step-by-step analysis processes and results is included in the Supporting Information. SSE study III: Evaluation of the performance of method IV. SSE study III was performed to evaluate the performance of method IV by comparing to methods I and II. The same set-up was used for the simulation as for SSE study II, except that the values of τ were smaller in SSE study III (Table 4) to represent low-efficacy ligands. Then, for the parameter estimation, each simulated data were analysed by three different estimation methods: method I with E m set to true; method II with K A values set to true; and method IV. Finally, the results of a total of 30 SSE units were obtained from the post-estimation analysis.
Results
Systematic assessment of the identifiability of both the operational model and the general operational model
Structural identifiability of the operational model. Given pharmacological response data only, the original form of the operational model (Equation 1) was confirmed as not structurally identifiable. As conceptually demonstrated in Equation 4 (a re-expression of Equation 1 by dividing K E ), there were infinite possible combinations of R 0 and K E that rendered the same result. For example, the two parameter sets, (R 0 = 100, K E = 20, K A = 10 À8 ) and (R 0 = 10, K E = 2, K A = 10 À8 ), produced exactly identical curves.
Structural identifiability analysis was performed in Equation 1. As shown in Figure S1A , the result indicated that this equation was unidentifiable when all parameters were considered to be estimable. Fixing either R 0 or K E rendered the model structurally identifiable. In the absence of measuring (or estimating) R 0 or K E from an additional experiment, it is not possible to distinguish their values. In order to solve this problem and as indicated by the work of Black and Leff, R 0 and K E are therefore reduced into a single identifiable quantity ( R0 KE ), defined as the transducer ratio τ. This yielded the reduced form of the operational model, Equation 5, which was structurally identifiable ( Figure S1B) .
Deterministic identifiability of the operational model. It was seen from the results of a deterministic identifiability analysis (Figure 1 ) that the operational model (Equation 5) generally Table 4 The parameter values for the SSE studies Functional selectivity quantification yielded appropriately low RSE% values (<50%) for τ and K A for standard study designs. However, it was also evident that the precision of the estimate of both K A and τ decreased with increasing values of τ, indicating that the operational model would not be deterministically identifiable for the large values of τ, even though this model is structurally identifiable (Figure 1 ). This is conceptually demonstrated in Equations 6 and 7: when values of τ greatly exceed 10 (i.e. highly efficacious ligand), Equation 5 is well approximated by Equation 6, which is then unidentifiable. Equation 6 is re-expressed as Equation 7 by dividing K A . We now see that τ and K A only appear as the ratio when τ exceeds 10 and hence there will be infinite possible combinations of τ and K A that provide indistinguishable results (i.e. the model is structurally unidentifiable).
In order to circumvent this problem, the transduction coefficient (R) was introduced, defined as the ratio between transducer ratio (τ) and equilibrium dissociation constant (K A ). Substituting R into Equation 5 yielding Equation 8:
A deterministic identifiability analysis was also performed on Equation 8. Contrary to the behaviour of K A , the RSE of R is now independent of the value of τ (Figure S2 ), indicating that the transduction coefficient (R) could be precisely estimated, even for highly efficacious ligands. In this sense, R was not only a combination of efficacy and affinity, as originally described, but also the minimal robust element that could be directly derived from the operational model analysis for quantifying agonism. Figure S3A , the result indicated that this equation was unidentifiable when all parameters were considered to be estimable. Furthermore, case deletion assessment ( Figure S3B-D) identified that the general operational model had one unidentifiable parameter and one of E m , log(K A ), or log(R) would be required to be fixed to yield a structurally identifiable model. However, since log(R) is regarded as the target from these analyses, only E m or log(K A ) could be considered to be fixed. Note here that neither n nor Basal affects the structural identifiability of the model. Table 5 , in general, with fixed E m or K A , the target parameter R could be precisely estimated with low RSE% values (<50%), when at least one highly efficacious ligand existed. For a pair of lowefficacy ligands, estimation of R became less precise and fixing E m gave more precise parameter estimation of R than fixing K A . For all highly efficacious ligands, given only
Structurally identifiability of the general operational model. Structural identifiability analysis was performed on Equation 2. As shown in
Deterministic identifiability of the general operational model. A deterministic identifiability analysis was performed on Equation 2 for a pair of ligands. As shown in
Figure 1
The RSE of estimated parameters versus τ for Equation 5. In this study, a generic study design with sampling concentrations log(A) from À13 to À4, increment of 1, was adopted. A proportional measurement error with 10% coefficient of variation were assumed. K A was set to an arbitrary value, 10 À8 mol·L À1 . The deterministic identifiability was assessed for each value of τ, ranging from 0.1 to 100. The left panel is for K A and the right panel is for τ. The red dashed line indicates the 50% RSE, considered as the threshold for precise estimation.
pharmacological response data, K A could not be precisely estimated (RSE% values >100%), consistent with previous findings in the operational model.
Evaluation of the effects of parameter mis-specification on the quantification of ligand bias
The source of parameter mis-specification addressed here was restricted to some unavoidable cases, that is, theoretically inevitable mis-specification or simply fixing the parameter to an (arbitrary) value for convenience. Note that the effects of mis-specified K A arising from binding assay experimental error, while potentially important, was not considered on the performance of method II and was beyond the scope of current evaluation. In method I, E m was prone to mis-specification. In real cases, the true value of E m is rarely known and often empirically approximated from the maximal observed response among a number of ligands or the response to a known maximal stimulant (e.g. forskolin for cyclic AMP) (Evans et al., 2011; Kenakin et al., 2012) . In so doing, E m is set to the lower bound of its true value. On the other hand, K A is simply fixed to an (arbitrary) value for convenience in method III. The influence of the mis-specified E m . In the case where the slope factor (n) is equal to one, an exact numerical evaluation was performed to explore the effects of the misspecification of E m (see Appendix A). It is clearly shown that the mis-specified value of E m leads to an inaccurate estimation of R. Here, we are referring to the mean error in the estimate of R, which we specify as the true value minus the estimated value [we use mean error to avoid the use of bias in two different settings (statistical and pharmacological)]. The mis-specification of R has a similar effect on different ligands. Therefore, the normalization process would cancel out this estimation mean error, and the estimation of Δ log (R) would remain accurate. In other words, the estimation of Δ log (R) is tolerant to the misspecification of E m .
Instead of plugging in estimated
Table 5
The results of deterministic identifiability analysis of the general operational model a High = high efficacy and low = low efficacy. b If the RSE value is less than 50%, the parameter it describes is interpreted as precisely estimable.
Table 6
The results from the evaluation of the effects of the mis-specified E m on the estimation of log(R) and Δ log (R) 
Functional selectivity quantification
For the case where the slope factor is different from unity, a stochastic simulation-estimation study was performed to explore the effect of the mis-specification of E m . In Table 6 , it is noted that estimation of log(R) is inaccurate with the mis-specified E m . For instance, in the case that n is equal to 0.7 and E m is underestimated by 20%, the estimated log(R) values for ligands I and II were 3-5% greater than their true values (i.e. negligibly affected). The estimation mean error of ligand bias caused by the misspecification of E m appears therefore to be largely cancelled out via the normalization process.
The influence of mis-specified K A . As shown for the misspecification of E m , we can exactly determine the effect of the mis-specification of K A on estimation mean error (detailed in Appendix B). Through the derivation, it is evident that the mis-specification of K A would lead to inaccurate estimation of R. However, again, this affects all ligands in question equally, and hence, estimation of Δ log (R) remains accurate.
When the slope factor was different from unity, we performed a stochastic simulation-estimation study to explore the influence of the mis-specification of K A . In Figure 2 , it is demonstrated that Δ log (R) calculated from method III (red) is essentially accurate, even when the slope factor n departs from unity. It is also seen that arbitrarily assigning K A to 1-mol·L À1 (method III, red line) is indistinguishable from the result produced from plugging in the true values of K A (method II, blue line), indicating that the influence of this mis-specification of K A on the quantification of ligand bias is trivial.
Assessment of the relaxation of the need for a full agonist in quantifying functional selectivity
It was shown in the deterministic identifiability analysis that estimation of log(R) after fixing E m (method I) or fixing K A (method II) became less precise in the absence of highly efficacious ligands (Table 5) . Moreover, the application of method III was restricted, by definition, to cases wherein a full agonist (highly efficacious ligand) was used in the experiment. Method IV was proposed to relax the need for a full agonist in method III. In this case, E m was taken to be the highest efficacy level observed within the range of ligands considered.
Figure 2
Values of Δ log (R), with its 95% CI, over different values of n. The green line shows the true value. Dashed line indicates the median estimated value and the dash-dot line the 95% CI of estimated value. Blue indicates the method of assigning K A to measured values from binding assay (method II); red indicates the method of arbitrarily fixing K A of full agonists to 1 (method III). The successful estimation rates of three methods were all higher than 95%. A stochastic simulation-estimation study was performed to compare the performance of method IV with other estimation methods, that is, methods I (E m set to the system maximal response) and II (K A set to the value from a previous binding experiment). Method III was excluded from this comparison because it, by definition, could only be applied to the case that a full agonist was present.
The method IV estimation of log(R) was found to be robust (using GraphPad Prism v7.0), with a successful estimation rate close to 100%. Methods I and II, however, had quite poor rates of successful estimation (less than 60%), especially for large values of n ( Figure 3A) . This suggests that method IV is more robust than typical analysis methods. Furthermore, in Figure 3B , it was clear that the Δ log (R) calculated using method IV was either accurate or minimally inaccurate within the normal range of n (from 0.5 to 2).
An exact numerical evaluation (detailed in Appendix C) supports these findings, showing that method IV yields an accurate Δ log (R). As demonstrated before, the influence of misspecified K A can be cancelled out through the normalization process. Hence, the estimation of Δ log (R) is accurate using method IV. As demonstrated in Appendix C, fixing K A for a given partial agonist to an arbitrarily large value (1 mol·L À1 )
forces the apparent value of τ (τ 0 ) to be sufficiently large for estimation of R to be precise, despite its lower efficacy. Furthermore, it is noted in the deterministic identifiability analysis that a large value of τ contributes to the precise estimation of transduction coefficient (R). Hence, R and therefore Δ log (R) can be precisely estimated in method IV.
Discussion and conclusions
Functional selectivity describes the ability of ligands to differentially regulate several different signalling pathways when coupled to a single receptor (Clarke and Berg, 2010) . This is a complicated pharmacological process involving multiple biological steps (e.g. receptor binding, cellular and intracellular signalling), and how these multiple signalling pathways interact with the receptor is still unclear (Kenakin and Christopoulos, 2013b) . Due to the complexity of functional selectivity, the implementation of a full model that can accommodate multiple receptor states where each state links to a signalling pathway remains impractical (Weiss et al., 1996; Ehlert, 2008; Stein and Ehlert, 2015) . Therefore, it has been necessary to use a simplified model. Several simplified models have been proposed, such as the three-state model (Leff et al., 1997) , the operational model (Black and Leff, 1983) , the operational model with non-zero constitutive activity (Slack and Hall, 2012 ) and the conformation-based operational model (Roche et al., 2013) . Among them, the simplest version is the operational model (Black and Leff, 1983) , which has been widely used to quantify functional selectivity (Kenakin et al., 2012) .
The purpose of the current study is to gain a more indepth understanding of the application of the operational model for quantification of functional selectivity. To do this, we first systematically assessed identifiability of the operational model and the general operational model (where basal and system maximum are also considered as parameters). In so doing, additional rationale has been provided for utilization of current metrics for the quantification of functional selectivity. Second, current estimation methods for the quantification of ligand bias were evaluated via both exact (algebraic) and numerical (stochastic simulationestimation) approaches, with the goal of providing a better understanding of the effect of parameter mis-specification. Finally, based on the insights from these evaluations, the current method was further generalized into a more robust and objective procedure that has the potential to simplify current analyses.
In many cases, metrics arise from a need to solve the mathematical issue of quantification. For instance, the parameter τ was introduced to reduce two entangled parameters, R 0 and K E , into one single parameter (Black and Leff, 1983) . While this parameter may not have biological meaning, its form is a necessary part of the application of the operational model. Likewise, the transduction coefficient R, the ratio of τ to K A , was initially constructed to simultaneously account for both affinity and efficacy of a ligand (Kenakin and Miller, 2010) . However, we see that this was also required mathematically to ensure that the model parameters were able to be estimated with reasonable precision. The issue of parameter estimation is only evident for highly efficacious ligands, where the value of τ is sufficiently large (say, 10) such that the model collapses to the ratio of τ to K A (namely, R). In other words, with only functional response assay data (and no binding data), R is the minimal element that can be directly derived from the operational model.
The normalized transduction coefficient, Δ log (R), was initially designed to cancel out the system bias and observation bias in the in vitro assays (Kenakin et al., 2012) . Through our analysis, we have found that this metric could also cancel out the possible estimation mean error introduced by the mis-specification of fixed parameters. In other words, the value of Δ log (R) would be accurate even when E m and K A were unknown and their values fixed (hence mis-specified). This makes Δ log (R) an important, robust quantity in current practice. Therefore, there is no need to run a separate assay to determine an accurate estimate of E m or K A , when the aim of study is to quantify ligand bias based on ΔΔ log (R). In so doing, our work helps alleviate the concern that may arise on fixing K A to a non-physiological value (1 mol·L À1 ), instead of plugging in realistic value estimated from binding assay (Rajagopal, 2013; Onaran et al., 2014) . In this work, we propose a generalization of the accepted method III, whereby each experiment must include a full agonist which is used as an approximation to the system maximum (E m ). Compared to the accepted method, the only modification made in the proposed method (method IV) is to relax the requirement of a full agonist and select the ligand with the highest efficacy level among the tested ligands as if it were a full agonist (termed a 'pseudo full agonist'). Hence, method IV inherits most of the advantages and limitations of method III; only functional assay data are required, and the estimation of operational model parameters is inaccurate but tolerated due to the subsequent normalization. We also found that method IV provides more precise estimation results even in the absence of highly efficacious ligands. As efficacy profiling of ligands is not required, method IV (using the maximum effect from the entire range of ligands as an approximation to the system E m ) therefore has the potential to be applied to large-scale screening to accelerate the discovery of novel lead compounds with desirable features of functional selectivity.
The choice of the various methods (I-IV) for estimating the parameters from the operational model largely depends on the aim of the work and the available data. If the aim is solely to calculate, Δ log (R) and/or ΔΔ log (R) for the quantification of ligand bias, it is our recommendation that method IV be chosen. However, if an accurate estimate of E m , K A , R and τ is the target, then methods I or II would be more appropriate. In addition, with more information at hand (e.g. binding assay data and separate E m information), it is possible to gain insights into the system via methods I or II, which is not available from methods III or IV where these values are compressed (Buchwald, 2017) .
A limitation of the current study is that we did not consider biological constraints associated with different pathways. In this work, we consider a range of values of n to encompass values that are seen in empirical applications of the operational model. We do not attempt to provide a mechanistic interpretation of the value. Method II, in its original form (Rajagopal et al., 2011) , fixes the K A from different pathways to the same empirical dissociation constant, determined from a binding assay under conditions that would limit the formation of a receptor ternary complex. However, the feasibility of this biological constraint is still under debate (Rajagopal, 2013; Kenakin and Christopoulos, 2013a) . There is emerging evidence that a single value of K A cannot describe data from a ligand that acts as the weak agonists in two pathways with very different EC 50 values (Kenakin and Christopoulos, 2013a) . Through the theoretical analysis from (cubic) ternary complex model, the binding affinity of agonist can be affected by allosteric modulation of effector (G protein) and different receptor states (Weiss et al., 1996; Ehlert, 2008; Stein and Ehlert, 2015) . This may explain the reason why a single binding affinity may be insufficient to describe a biological system. Therefore, in the evaluation of the methods in this work, we allowed the K A values to be different in different pathways. In so doing, the performance of the current method II (without the potentially necessary biological constraint on K A ) should always be superior to its original version (which included the biological constraint).
It is noted that in Figure 2 that the 95% CI becomes narrower along the range of evaluated n values (i.e. yields more precise parameter estimation). Yet, in Figure 3A , there is a decrease in the successful estimation fraction with an increase in n, and Figure 3B shows wider 95% CI with the increment of n (i.e. less precise estimation). These directly opposite behaviours may be due to the difference of the ligand efficacy in two scenarios presented in the two figures. Figure 2 is a case of a highly efficacious ligand (large value of τ, τ is greater than 1) whereas Figure 3 considers low efficacious ligands (low value of τ, τ is less than 1). From the equation
when τ is greater than 1, the increment of n would increase the value of τ n τ n þ1 (more efficacious), while, when τ is less than 1, the increment of n would decrease the value (less efficacious). Hence, it is speculated that for the same method, more efficacious ligands will have a narrower 95% CIs (i.e. more precise estimation).
Our work provides a formal assessment of the issues pertaining to identifiability and other mathematical observations that have been raised by others (Ehlert, 2005; Kenakin et al., 2012; Rajagopal, 2013; Kenakin and Christopoulos, 2013a; van der Westhuizen et al., 2014) . For instance, it was noted that two different parameter sets were able to produce nearly identical curves in the general operational model (Kenakin et al., 2012) , which is a function of observability (rather than identifiability, per se). It has also been reported that separate estimation of τ or K A values for full agonists from direct fitting of the operational model to a concentration-response curve was usually not possible (Rajagopal, 2013; van der Westhuizen et al., 2014) , which was explored here with deterministic identifiability. To our knowledge, the current study provides the first formal assessment of the identifiability of commonly used models in functional selectivity, illustrating the utility of identifiability analysis tools developed in the field of pharmacometrics (Bazzoli et al., 2010; Shivva et al., 2013) . This recent trend in quantitative pharmacology sees the development of more mechanism-based models, which are inevitably more complicated in their interrelationships but are built from the building blocks provided by standard receptor theory (Wajima et al., 2009; Peterson and Riggs, 2012; Benson et al., 2014) . It is therefore likely that the models explored here, based on the operational model, will form the basis of many other models within quantitative systems pharmacology, which require appropriate mathematical underpinning.
In conclusion, we have systematically assessed the identifiability of the operational model and its variants and demonstrated that current methods for quantifying ligand bias is tolerant to mis-specification of those parameters that are set to fixed constants. Furthermore, an objective method is proposed that relaxes the need for specific choice of ligands in any given experiment and provides accurate estimates of biased ligand profiles.
Declaration of transparency and scientific rigour
Equations A6 and A7 for ligand two yielded the expressions for τ 0 2 and K 0 A2 :
Similarly, R 0 2 was derived:
Combining Equations A17 and A20 yielded the expression for Δ log (R 0 ):
Through the derivation above, it was clearly shown that a mis-specified value of K A could lead to inaccurate estimation of R, while the estimation of Δ log (R) was still accurate when the slope factor was equal to unity. The estimation mean error caused by the mis-specification of K A has been completely cancelled out via normalization process.
Appendix C
Theoretical assessment of the feasibility of method IV
Method IV could be considered a natural generalization of method III. The requirement of full agonist was relaxed into the ligand with highest efficacy among all the ligands in the study.
The general operational model has only one unidentifiable parameter, that is, fixing either E m or K A will render the model structurally identifiable. Therefore, with mis-specified K A , the estimated values of other parameters have to change accordingly in line with the constraints from observed features of the concentration response curve (e.g. E max and EC 50 ).
The location parameter EC 50 of the general operational model was derived as follows:
Similarly, this constraint should also be applied to the case that K A was fixed to 1 mol·L À1 , as shown in Equation A23
.
Transforming Equation A23 yielded the expression for the apparent value of τ (denoted here as τ 0 ) when K A was misspecified to 1 mol·L À1 :
As the normal value of EC 50 was much smaller than 1 mol·L À1 (10 À4~1 0 À12 mol·L À1 ), the apparent value (τ 0 ) appeared to be much larger than 1. In other words, setting K A to 1 ensured the apparently high efficacy of the ligand. In method IV, fixing K A to 1 mol·L À1 was not the result from a full agonist, but rather a 'pseudo full agonist' was created by fixing K A to 1 mol·L À1 for the highest efficacy agonist in the set of compared agonists. Furthermore, as noted in the previous deterministic identifiability analysis, the large apparent value of τ (i.e. highly efficacious ligand) could also substantially improve the estimation precision of parameter R. Method IV could also be considered as the generalization of method I. The asymptote parameter E max of the general operational model was derived as follows:
Similarly, this constraint should also be applied to the pseudo full agonist, as shown in Equation A26.
Reorganizing Equations A26 yields A27:
As demonstrated before, when K A was assigned to 1-mol·L À1 , the apparent value of τ (τ 0 ) was much larger than 1.
Therefore,
could be reduced to E max , that is, E m was implicitly fixed to the E max value of the pseudo full agonist in method IV, rather than the system maximal response.
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Additional Supporting Information may be found online in the supporting information tab for this article. should have a continuous linear log-log relationship with the log of the random noise and (ii) |M F | should approach infinity as residual variance approaches zero. Figure S2 The relative standard error of estimated parameters vs. τ for Eq. 8. In this study, a generic study design with sampling concentrations log (A) from À13 to À4, increment of 1, was adopted. A proportional measurement error with 10% coefficient of variation were assumed. K A was set to an arbitrary value, 10 À8 mol L À1 . R was defined as the ratio of τ and K A . The deterministic identifiability was assessed for each value of, ranging from 0.1 to 100. The left panel is for K A and the right panel is for R. The red dashed line indicates the 50% relative standard error, considered as the threshold for precise estimation. Figure S3 log|M F | vs. log residual variance for general operational model (Eq. 2). A) all parameters estimated (E m , Basal, n, log (K A ), log (R)); B) E m fixed; C) log (K A ) fixed; D) log (R) fixed. Figure S4 Concentration-response curves for cAMP formation showing pplss-3HA-hCB1 HEK signalling, on stimulation with 2.5 μM FSK and a panel of six agonists, following >16 h pretreatment in the presence of PTX. The data is fitted by Method IV. Table S1 The estimation of transduction coefficient (log (R)) via Method IV.
